Physician profile
Sara Joy Risner-Rumohr
NPI 1922319334
$4,631.94
in general payments reported to CMS, 2019-2025
29 companies · $854 in 2025
The $854 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2021: $470 · 2022: $707 · 2023: $740 · 2024: $1,229 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,625 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,625.09 |
| Education | $198.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $941.48 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Sun Pharmaceutical Industries INC. | $415.23 | 2019-2025 | Blu-U, Odomzo, Ilumya |
| Dermavant Sciences, INC. | $395.31 | 2023-2024 | Vtama |
| Pfizer INC. | $380.38 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $347.53 | 2019-2025 | Libtayo, Dupixent |
| Janssen Biotech, INC. | $297.88 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Arcutis Biotherapeutics, INC. | $268.65 | 2023-2025 | Zoryve |
| Genzyme Corporation | $232.33 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $221.56 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $216.16 | 2021-2024 | Siliq, Duobrii |
| Ucb, INC. | $158.68 | 2019-2025 | Bimzelx |
| Amgen INC. | $135.85 | 2023-2025 | Otezla, Enbrel, Otezla |
| Leo Pharma INC. | $96.89 | 2023-2025 | Adbry |
| Organon LLC | $67.73 | 2024-2025 | Vtama |
| Genentech USA, INC. | $51.83 | 2019-2025 | Xolair |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $51.24 | 2022-2024 | Sotyktu |
| Mimedx Group, INC. | $45.96 | 2024-2025 | |
| Galderma Laboratories, L.P. | $36.95 | 2019-2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $36.93 | 2019-2022 | |
| Incyte Corporation | $36.72 | 2022 | |
| Lilly USA, LLC | $35.39 | 2023-2024 | Taltz, Olumiant |
| Helsinn Therapeutics (U.S.), INC. | $31.35 | 2023-2025 | Valchlor |
| Kyowa Kirin, INC. | $22.82 | 2022 | |
| Dermira, INC. | $21.47 | 2019 | |
| Merz North America, INC. | $21.17 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.54 | 2023 | Cyltezo |
| Prugen, INC. Pharmaceuticals | $18.61 | 2019 | |
| Dusa Pharmaceuticals, INC. | $14.47 | 2019 | |
| Epi Health, LLC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Risner-Rumohr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.